JNJ Johnson & Johnson

142.21
+1.76  (+1%)
Previous Close 140.45
Open 141.25
Price To Book 6.41
Market Cap 377,575,511,911
Shares 2,655,055,987
Volume 7,335,505
Short Ratio 1.87
Av. Daily Volume 6,924,079

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Phase 3 discontinuation announced October 17, 2017.
Talacotuzumab
Acute myeloid leukemia (AML)
Approval announced February 14, 2018.
Apalutamide
Non-metastatic castration-resistant prostate cancer (CRPC)
FDA Approval announced July 17, 2018.
D/C/F/TAF
HIV
Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Approval announced October 30, 2017. sNDA flled December 14, 2018. Estimated PDUFA date October 11, 2019.
XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
FDA Approval announced October 30, 2018.
INVOKANA CANVAS
Type 2 diabetes
sNDA filing announced March 28, 2019. Priority review announced May 22, 2019. Estimated PDUFA date September 27, 2019.
INVOKANA - CREDENCE
Diabetic Kidney Disease
Approval announced May 7, 2018.
DARZALEX (Daratumumab) - ALCYONE
Frontline multiple myeloma (non-transplant)
FDA approval announced March 5, 2019.
Esketamine
Treatment resistant depression
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Approval announced October 13, 2017.
STELARA (USTEKINUMAB)
Plaque psoriasis
Approval announced October 20, 2017.
SIMPONI ARIA
Psoriatic arthritis (PsA)
Approval announced October 20, 2017.
SIMPONI ARIA
Ankylosing Spondylitis
Approval announced July 13, 2017.
Guselkumab
Plaque psoriasis
CRL issued September 22, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.
Sirukumab
Rheumatoid arthritis
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
sNDA approval announced February 8, 2018.
ZYTIGA (abiraterone acetate) - LATITUDE
metastatic hormone-naïve prostate cancer (mHNPC)
FDA Approval announced April 12, 2019.
Erdafitinib
Urothelial cancer
NDA filing announced April 29, 2019. Estimated PDUFA date April 28, 2020.
Dolutegravir + rilpivirine
Injectable 2DR in HIV
Announced May 18, 2018 that dosing will be stopped.
Atabecestat
Alzheimer’s disease
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Phase 2/3 trial initiation announced July 11, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
Phase 2 trial initiation announced November 19, 2018.
Guselkumab (NOVA)
Hidradenitis Suppurativa
sBLA filing announced March 12, 2019. Estimated PDUFA date January 10, 2020.
Daratumumab - MAIA
Newly Diagnosed Multiple Myeloma (NDMM)
Phase 3 primary endpoint met - December 12, 2018.
Guselkumab vs Cosentyx - ECLIPSE
Psoriasis
Phase 2a initiation announced January 17, 2019.
Guselkumab
Ulcerative colitis
sBLA filed December 20, 2018. Estimated PDUFA date December 19, 2019.
STELARA (USTEKINUMAB)
Ulcerative colitis
sNDA filing announced April 29, 2019. Estimated PDUFA date February 28, 2020.
Apalutamide
Metastatic castration-sensitive prostate cancer (mCSPC).
Phase 2 initial data to be presented at ASCO GU February 14, 2019. ORR 40%.
Niraparib (Galahad)
Castration-Resistant Prostate Cancer
Approval announced February 27, 2019.
Guselkumab
Plaque psoriasis
sNDA filing announced March 26, 2019. Estimated PDUFA date January 24, 2020.
Daratumumab + VTD
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)

Latest News

  1. The Value of Best-in-Class Management
  2. Billions at Stake in Opioid Suits, But It's No Tobacco Windfall
  3. Big Drugmakers That May Tread the M&A Path After Pfizer
  4. 5 Large-Cap Stocks With Low Price-Sales Ratios
  5. Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
  6. Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
  7. J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
  8. 5 Top Stocks to Protect Your Portfolio
  9. Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion
  10. Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
  11. The Opioid Epidemic Will Be A Yearslong Overhang For These Pharma Stocks
  12. Johnson & Johnson Made the Right Call in Fighting Oklahoma Over Opioids, Analyst Says
  13. Market Morning: Huawei Strikes Back, ‘No’ on No No Deal, Ancient Chinese Stoners, Crowded CrowdStrike
  14. Johnson & Johnson and Cisco Directors Are Buying Up Stock
  15. Jim Cramer: A Tale of Two Stocks
  16. Pharma Giant Nears Two-Decade Low As Opioid Settlement Remains In Limbo
  17. Why This Dow Jones Pharmaceutical Giant Is Trying To Break Out
  18. Teva Retests Lows After Judge Declines Settlement Offer
  19. Traders Look to Buy Global Health Care Stocks
  20. Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know